This is a type of chronic leukemia that affects the myeloid cells, which are precursors to red blood cells, white blood cells, and platelets. It's caused by a specific genetic change in the cells. It often starts slowly but can progress over time to a more aggressive phase.
Every report comes from a Lived member, sent anonymously.
Have you tried Gleevec (Imatinib) for CML (Chronic Myeloid Leukemia)?
Chronic myeloid leukemia (CML) is a cancer of the blood-forming cells in the bone marrow. It causes the marrow to make far too many white blood cells of a type called granulocytes, which build up in the blood and gradually crowd out healthy cells. "Chronic" means it usually develops slowly. Many people have no symptoms at diagnosis, and CML is often found when a routine blood test shows an unusually high white blood cell count. When symptoms do appear, they tend to be vague: tiredness, unexplained weight loss, drenching night sweats, fever, and pain or a feeling of fullness under the left ribs. That last symptom comes from an enlarged spleen, which can also make someone feel full after eating only a little. CML is described in three phases, based on the share of blasts (very immature leukemia cells) in the blood and bone marrow. Most people are diagnosed in the chronic phase, when blasts make up fewer than 10% of cells. If the disease is not controlled, it can move to an accelerated phase (10% to 19% blasts) and then a blast phase (20% or more), which behaves like a fast-growing acute leukemia. Since targeted pills became available, most people diagnosed in the chronic phase respond well, and CML is now usually managed as a long-term condition.
CML starts with a genetic change inside a single bone marrow cell during a person's lifetime. Pieces of chromosome 9 and chromosome 22 break off and swap places, leaving a shortened chromosome 22 known as the Philadelphia chromosome. The swap joins two genes, BCR and ABL1, into one abnormal fusion gene, written BCR::ABL1 (or BCR-ABL). That gene produces a tyrosine kinase, an enzyme that acts like a growth switch stuck in the on position, so the affected cell and its descendants keep multiplying. This same abnormal protein is what modern treatment is designed to block. The change is acquired, not inherited. It is not passed from parent to child, and a family history of CML does not appear to raise risk. In most people, why the swap happens is unknown. The few known risk factors are getting older (the average age at diagnosis is about 66, and CML is rare in children), being male, and exposure to high-dose radiation, such as from a nuclear accident or earlier radiation treatment for another illness. Smoking, diet, chemical exposures and infections have not been shown to affect the risk.
A blood test usually raises the first suspicion. A complete blood count (CBC) measures red cells, white cells and platelets. In CML the white cell count is typically very high, and looking at the blood under a microscope shows white cells at many stages of maturity. A physical exam checks whether the spleen is enlarged. The diagnosis is confirmed by finding the Philadelphia chromosome or the BCR::ABL1 gene. Cytogenetic testing and FISH (fluorescence in situ hybridization) look for the chromosome swap in cells. A quantitative PCR (polymerase chain reaction) blood test measures how much BCR::ABL1 genetic material is present, and that first result becomes the reference point for tracking treatment later. A bone marrow aspiration and biopsy, in which a needle removes a small sample of marrow and bone, usually from the hip bone after the area is numbed, shows the proportion of blasts and therefore the phase. Doctors may also calculate a risk score that estimates how likely chronic-phase CML is to progress, which helps guide the choice of first medicine.
The standard first treatment for chronic-phase CML is a tyrosine kinase inhibitor (TKI), a targeted pill taken every day that blocks the abnormal BCR::ABL1 protein. Unlike traditional chemotherapy, which attacks fast-growing cells in general, a TKI acts on the specific signal driving the leukemia. Most people in the chronic phase respond well, and the medicine keeps the disease under control for as long as it is taken. Several TKIs can be used as a first treatment: imatinib (Gleevec, also sold as a generic), dasatinib (Sprycel), nilotinib (Tasigna), bosutinib (Bosulif) and asciminib (Scemblix). For long-term survival, the established options perform similarly. The newer drugs tend to produce faster and deeper responses, which matters more for people with higher-risk disease or for those hoping to stop treatment someday. The choice usually depends on the risk score, other health conditions, likely side effects, other medicines a person takes, and cost. Tiredness, nausea, diarrhea, muscle aches, rash and fluid retention are common across the group. Some TKIs also carry particular risks to the heart, blood vessels, lungs or pancreas, which shapes who should take them and how they are monitored. If the first TKI doesn't work well enough or causes side effects that can't be managed, adjusting the dose or switching drugs is common. Testing the leukemia for mutations in BCR::ABL1 helps choose the next option. One mutation, T315I, makes most TKIs ineffective but can be treated with ponatinib (Iclusig) or asciminib. TKIs interact with many prescription and over-the-counter medicines, supplements and some foods, including grapefruit, so the care team needs a complete, current list before anything new is started. TKIs are not normally used during pregnancy because they may harm a fetus. Anyone who could become pregnant should plan this with the care team; interferon, an older injected treatment, can often be used during pregnancy instead. An allogeneic stem cell transplant, which replaces the bone marrow with cells from a donor, offers the best chance of cure but carries serious risks. It is generally reserved for people whose disease has resisted at least two TKIs or has reached an advanced phase, and is considered more often in younger people who have a matched donor.
For most people diagnosed in the chronic phase, CML now behaves like a serious but manageable long-term illness. Population studies show that life expectancy for people treated in the TKI era has come close to that of the general population, although each person's outlook depends on the phase at diagnosis, how well the disease responds, age and overall health. Most people stay on a TKI for many years. Daily life usually centers on taking the pill consistently. Missing doses or taking the wrong dose is linked to worse outcomes, so it helps to build the medicine into a routine and to tell the care team about side effects, cost or other problems rather than quietly skipping doses. Some side effects ease over time, and others can be managed by adjusting the dose or changing drugs. Monitoring is regular and long-term: check-ups at least every 3 months during the first year, then typically every 3 to 6 months. The key measure is the PCR test, reported on the International Scale (IS) as a percentage of a standardized starting level. A result of 10% or less at 3 months suggests treatment is on track, 1% or less is the target at 6 months, and 0.1% or less by 12 months is called a major molecular response, a thousandfold drop. A deep molecular response, 0.01% or lower and sometimes reported as undetectable, is the longer-term goal. If milestones are missed, the team checks whether doses are being missed, may test for mutations and may change the medicine. Some adults whose response has stayed deep for at least 2 years, after at least 3 years on a TKI, can try stopping the medicine under frequent blood testing, called treatment-free remission. CML comes back in some people, but it typically responds again when the medicine is restarted promptly. Living with an ongoing cancer can be stressful, and counseling, support groups and a written survivorship plan can help. People with CML also have a somewhat higher risk of certain other cancers, so routine cancer screening remains important.
See a doctor if you have ongoing unexplained tiredness, weight loss, drenching night sweats, or fullness or pain under the left ribs, or if a blood test has shown a high white blood cell count that hasn't been explained. During treatment, contact your care team promptly about a fever or other signs of infection, unusual bruising or bleeding such as frequent nosebleeds or bleeding gums, sudden weight gain or swelling, or side effects that make it hard to keep taking your medicine. Also report a return of fevers, bone pain or a full feeling under the left ribs, since these can mean the leukemia is becoming more active. Chest pain, sudden shortness of breath, a fast or irregular heartbeat, dizziness or fainting while taking a TKI needs medical help right away, because several of these medicines can affect the heart and blood vessels.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with CML (Chronic Myeloid Leukemia) is like, what's helped you, or ask the community a question.